deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT00639951

Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation

Multicentric, Randomized,Controlled and Comparative Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation

Sponsor: Instituto Bioclon S.A. de C.V.

Conditions Snake Bite
Interventions A Antivipmyn ®
Updated 6 times since 2017 Last updated: Jul 18, 2016 Started: Jan 31, 2008 Primary completion: Jan 31, 2009 Completion: Mar 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Administrative reasons

This PHASE4 trial investigates Snake Bite and is currently terminated or withdrawn. Instituto Bioclon S.A. de C.V. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 11 months · monthly snapshotTerminated

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE4

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE4

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Instituto Bioclon S.A. de C.V.
Data source: Instituto Bioclon S.A. de C.V.

For direct contact, visit the study record on ClinicalTrials.gov .